Sanjivani Paranteral Limited

SANJIVIN

INE860D01013

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:56 2024-07-16 EDT			5-day change	1st Jan Change
213.7 ^INR	+1.21%		-1.84%	+18.66%

06-21	Sanjivani Paranteral Limited Appoints Abhay Milan Shah as Independent Director	CI
05-13	Sanjivani Paranteral Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Sanjivani Paranteral Ltd Announces Resignation of Directors

January 19, 2017 at 11:53 pm

Sanjivani Paranteral Ltd. announced that Mr. Mahendra Kalwankar and Mr. Narmdeshwar R Chaube, Directors of the Company have resigned as Directors with effect from December 30, 2016.

Latest news about Sanjivani Paranteral Limited

Sanjivani Paranteral Limited Appoints Abhay Milan Shah as Independent Director	06-21	CI
Sanjivani Paranteral Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-13	CI
Sanjivani Paranteral Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-13	CI
Sanjivani Parenterals CFO Steps Down	04-08	MT
Sanjivani Paranteral Limited Announces Board Changes	04-08	CI
Sanjivani Paranteral Limited Announces CFO Change	04-08	CI
Sanjivani Paranteral Forms New Unit	02-28	MT
Sanjivani Paranteral Limited Appoints Pooja Vijay Gohil as Company Secretary and Compliance Officer	02-05	CI
Sanjivani Paranteral Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-05	CI
Sanjivani Paranteral Limited announced that it has received INR 248.0466 million in funding from Nabs Vriddhii LLP, Plasma Commercials Pvt. Ltd., Venus Orchards Pvt. Ltd., Ashika Global Securities Private Limited	02-04	CI
Sanjivani Paranteral Limited announced that it expects to receive INR 248.0346 million in funding from Nabs Vriddhii LLP, Plasma Commercials Pvt.Ltd., Venus Orchards Pvt. Ltd, Ashika Global Securities Private Limited and other investors	12-18	CI
Sanjivani Paranteral Limited Announces Resignation of Ritu Puglia from the Position of the Company Secretary	12-15	CI
Sanjivani Paranteral Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-18	CI
Sanjivani Paranteral Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-24	CI
Sanjivani Paranteral Ties Up with Czech Republic-based Alevia Healthcare to Expand Business in EU	23-05-09	MT
Sanjivani Paranteral Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-06	CI
Sanjivani Paranteral Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-06	CI
Sanjivani Paranteral Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Sanjivani Paranteral Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Sanjivani Paranteral Limited Appoints Monika Amit Singhania as Independent Director	22-09-27	CI
Sanjivani Paranteral Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-08	CI
Sanjivani Paranteral Limited Announces Appointment of Ritu Puglia as Company Secretary	22-05-17	CI
Sanjivani Paranteral Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-17	CI
Sanjivani Paranteral Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-17	CI
Sanjivani Paranteral Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-14	CI

Chart Sanjivani Paranteral Limited

Duration

Period

More charts

Sanjivani Paranteral Limited is engaged in the business of manufacturing pharmaceutical products. Its product category includes antibiotic, anti-emetic, non-steroidal anti-inflammatory drugs (NSAID) and analgesic, antimalarial, calcium and vitamin, sedative, steroid, cardiovascular, anti-fibrinolytic, anti-coagulant, vasoconstrictor, inotropic agent, anti-spasmodic, multivitamin, nutrition, iron, NSAID and analgesic, analgesic anti spasmodic, analgesic, and NSAID. Its antibiotic includes Netilmicin Sulphate, Amikacin Sulphate, and Gentamycin Sulphate. Its anti-emetic includes Ranitidine Hydrochloride, Metoclopramide, Ondansetron, and Promethazine. Its NSAID and analgesic includes Acetaminophen Injection and Diclofenac Sodium Injection. Its calcium and vitamin include Methylcobalamin 500 mcg/ml and Nicotinic Acid 10 mg/ml. Its sedative includes Midazolam Hydrochloride, Diazepam, and Dobutamine Hydrochloride. Its Iron includes iron Sucrose. Its analgesic includes Metamizole.

Sector

Pharmaceuticals

Calendar

2024-07-21 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANJIVANI PARANTERAL LIMITED	+18.66%	29.88M
ELI LILLY AND COMPANY	+56.34%	848B
NOVO NORDISK A/S	+33.15%	627B
JOHNSON & JOHNSON	-0.01%	363B
MERCK & CO., INC.	+15.08%	318B
ABBVIE INC.	+13.05%	299B
ASTRAZENECA PLC	+14.83%	243B
NOVARTIS AG	+16.81%	225B
AMGEN INC.	+16.48%	179B
PFIZER, INC.	+4.01%	167B